Xbrane is a Swedish biosimilar developer with a proprietary manufacturing platform. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference products. Lead candidate Ximluci®, a biosimilar candidate to VEGF inhibitor Lucentis®, is under registration in Europe with a planned launch with STADA during the first quarter of 2023 and an envisaged US launch with BAUSCH + Lomb for the end of 2023